ELVN - CIK 0001672619
The table below shows Enliven Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $132.18M | $101.73M | $119.44M | $101.70M | $100.62M | $96.87M |
| Short-term investments | $320.22M | $375.83M | $371.07M | $187.85M | $191.21M | $215.52M |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $463.14M |
| $482.68M |
| $495.62M |
| $294.32M |
| $297.00M |
| $318.13M |
| Property, plant & equipment | $20.00K | $399.00K | $462.00K | $404.00K | $549.00K | $630.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $464.85M | $490.88M | $503.89M | $302.57M | $305.43M | $327.04M |
| Accounts payable | $1.64M | $1.43M | $2.35M | $1.56M | $1.02M | $1.08M |
| Total current liabilities | $11.49M | $14.65M | $15.21M | $13.97M | $17.03M | $22.11M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $11.49M | $14.75M | $15.41M | $14.27M | $17.03M | $22.11M |
| Retained earnings | -$370.79M | -$317.50M | -$297.35M | -$272.02M | -$220.29M | -$197.14M |
| Total equity | $453.37M | $476.12M | $488.47M | $288.30M | $288.40M | $304.93M |